Explore more
News
Sarepta Therapeutics, FDA
Digest more
Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, ...
We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
Fintel on MSN18h
Oppenheimer Upgrades Sarepta Therapeutics (SRPT)Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone ...
Sanmina reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.42 per share. The ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback